
|Articles|September 1, 2003
New Products & Services
Raritan, NJ-Ortho-McNeil Pharmaceutical has received FDA approval to market levofloxacin (Levaquin) for the treatment of chronic bacterial prostatitis caused by Escherichia coli, Enterococcus faecalis, or Staphylococcus epidermidis.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
2
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
3
Choosing salvage therapy after prostate cancer focal ablation
4
NDV-01 produces robust 9-month results in high-risk NMIBC
5


















